Home » Renovo Skin Healing Drug Fails to Meet Main Goal in Phase II Trial
Renovo Skin Healing Drug Fails to Meet Main Goal in Phase II Trial
Renovo Group PLC’s skin healing drug Juvidex failed to meet its primary goal in a Phase II trial, but did meet a number of secondary endpoints.
proactiveinvestors
proactiveinvestors
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May